Sade-Feldman and colleagues identified two distinct states of CD8+ T cells associated with patient tumor regression or progression and a single transcription factor, TCF7, which could predict positive clinical outcome in an independent cohort of checkpoint-treated patients11. The gene discussed is CD8A; the disease is neoplasm.